Stockscreener 앱 받기
2.67
2.20%
-0.06
전일 마감가:
$2.73
열려 있는:
$2.71
하루 거래량:
25,170
Relative Volume:
0.31
시가총액:
$1.50B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.95%
1개월 성능:
-40.13%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$2.66
$2.8879
1주일 범위
$2.61
$3.3983
52주 변동 폭
$2.5366
$6.25
Sl Science Holding Ltd Stock (SLBT) Company Profile
Compare SLBT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLBT
Sl Science Holding Ltd
|
2.67 | 1.55B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sl Science Holding Ltd 주식(SLBT)의 최신 뉴스
SLBT|SL Science Holding Ord Shs|Price:2.820|Chg%:-0.300 - TradingKey
SL Science Holding Ord Shs (SLBT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SL Science Holding Ord Shs (SLBT) Cash Flow - TradingKey
SL Science Holding Ord Shs (SLBT) Valuation: PE, PB & Fair Value Analysis - TradingKey
SL Science Holding Ord Shs (SLBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kwo Liang Chen Net Worth (2026) - GuruFocus
SLBT|SL Science Holding Ord Shs|Price:3.120|Chg%:-0.050 - TradingKey
SLBT|SL Science Holding Ord Shs|Price:2.620|Chg%:-0.500 - TradingKey
Ching Dong Wang Net Worth (2026) - GuruFocus
Mingche Liu Net Worth (2026) - GuruFocus
The Second Battlefield for Solid Tumor CAR-T: A Global Race in the Intracranial Arena -- Who Is Leading? - Yahoo Finance
Lok Sang Leung Net Worth (2026) - GuruFocus
SL Science presents glioblastoma treatment data at WCP 2026 - Investing.com UK
SL Science presents glioblastoma treatment data at WCP 2026 By Investing.com - Investing.com South Africa
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
SL Science Holding Limited Exhibits Breakthrough Gamma Delta T Cell Therapy for Glioblastoma at 2026 World Congress of Basic and Clinical Pharmacology - marketscreener.com
SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology - The Manila Times
SL Science Showcases Preclinical Gamma Delta T Cell Study Demonstrating Glioblastoma Elimination at WCP 2026 - Quiver Quantitative
Preclinical γδ T cells eradicated a brain tumor by day 26 at highest dose - Stock Titan
4DMedical Shares Plunge 15.57% to $3.20 as Volatile ASX Healthcare Stock's Wild Ride Continues This Week - International Business Times Australia
Ericsson, Q32 Bio and other big stocks moving lower in Tuesday’s pre-market session - MSN
Ericsson, Q32 Bio And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
SL Science seeks US orphan drug designation for γδ T-cell therapy - BioWorld News
Net current asset value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Number of employees of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Gross margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Price to book ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Net margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
SL Science Holding Limited (SLBT-Q) Stock Price and News - The Globe and Mail
Enterprise value to revenue forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Net debt of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Cash flow from investing activities of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Debt to assets ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Debt to equity ratio of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBITDA ratio of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value to EBITDA forward of SL Science Holding Limited – BOATS:SLBT - TradingView
EBITDA margin % of SL Science Holding Limited – BOATS:SLBT - TradingView
Enterprise value to EBIT forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to earnings forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to sales forward of SL Science Holding Limited – BOATS:SLBT - TradingView
Price to book forward of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Enterprise value of SL Science Holding Limited – NASDAQ:SLBT - TradingView
Return on equity % of SL Science Holding Limited – BOATS:SLBT - TradingView
Tangible book value per share of SL Science Holding Limited – BOATS:SLBT - TradingView
EBIT per share of SL Science Holding Limited – NASDAQ:SLBT - TradingView
EBIT per share of SL Science Holding Limited – BOATS:SLBT - TradingView
Sl Science Holding Ltd (SLBT) 재무 분석
Sl Science Holding Ltd (SLBT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.84%
0.86%
자본화:
|
볼륨(24시간):